With over 10 years of longitudinal data, Medial EarlySign’s data sets cover more than 20 million patient lives and 150 million patient years. They include geographically, ethnically, racially, and economically diverse populations with diverse health statuses.
For successful deployment in clinical practice, robust evaluation and study is a must. Currently, there are independent papers that have been published from studies conducted in 13 clinical study sites worldwide. With clinical evidence validated and published in multiple scholarly publications, our clinical data studies have demonstrated the validity and accuracy of our models.
Medial EarlySign has developed a hardened, secure HIPAA-compliant information architecture to protect patient data security. Additionally, internal procedures ensure high quality conduct of clinical studies in compliance with applicable international regulations and legal requirements. We safeguard the rights and well-being of participants, including privacy and confidentiality of their information, and the accuracy and completeness of the reported data.